Welcome to our dedicated page for Sight Sciences news (Ticker: SGHT), a resource for investors and traders seeking the latest updates and insights on Sight Sciences stock.
Sight Sciences reports recurring developments as an eyecare technology company developing and commercializing interventional ophthalmic devices for glaucoma and dry eye disease. Its news commonly covers financial results and guidance, segment trends in Interventional Glaucoma and Interventional Dry Eye, and clinical data for the OMNI Surgical System and TearCare System.
Company updates also address investor conference participation, intellectual property matters involving interventional glaucoma patents, and product positioning across minimally invasive glaucoma surgery and evaporative dry eye treatment. News about SGHT centers on commercialization, reimbursement-sensitive procedure adoption, clinical evidence, and operating performance in its ophthalmic device portfolio.
Sight Sciences has filed a lawsuit against Ivantis, Inc. in the United States District Court for Delaware, alleging infringement of four U.S. patents related to devices and methods for reducing intraocular pressure. The company seeks an injunction to stop the manufacture, use, and sale of Ivantis' Hydrus® Microstent, along with monetary damages for past infringements. CEO Paul Badawi stated this lawsuit aims to protect their market position in canalicular glaucoma surgery. Sight Sciences continues to innovate in glaucoma solutions, enhancing patient care through minimally invasive technologies.
Sight Sciences, a growth-stage medical device company (Nasdaq: SGHT), will participate in the Morgan Stanley Global Healthcare Conference on September 9, 2021, at 9:30 am ET. The event will be accessible via a live and archived webcast on their website. Founded in 2011, Sight Sciences focuses on addressing major eye diseases with innovative products like the OMNI® Surgical System and the TearCare® System. For more details, visit their official website.
Sight Sciences (Nasdaq: SGHT) has announced favorable results from a study published in Clinical Ophthalmology, demonstrating the long-term safety and efficacy of the OMNI Surgical System in treating open-angle glaucoma. The 24-month study showed a significant reduction in intraocular pressure (IOP) from 24.6 mmHg to 14.7 mmHg, alongside a decrease in medication use. The results indicate that 100% of subjects achieved at least a 20% IOP reduction. Adverse events were consistent with expected outcomes in similar surgeries, underscoring the potential for OMNI's expanded applications.
Sight Sciences reported impressive financial results for Q2 2021, with total revenue reaching $12.5 million, up 258% year-over-year. Surgical Glaucoma sales surged to $12.0 million, marking a 263% increase, while Dry Eye sales hit $0.5 million, up 169%. The gross margin expanded significantly to 82% from 40% in the previous year. Although the net loss widened to $17.6 million ($1.83 per share), the company completed a successful IPO, raising $253 million in July. For 2021, revenue guidance is projected between $46 million and $48 million.
Sight Sciences, Inc. (Nasdaq: SGHT) will announce its financial results for Q2 2021 on August 12, 2021, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET to discuss these results. The company focuses on developing medical devices aimed at prevalent eye diseases, currently marketing the OMNI® and TearCare® systems. Investors can access the conference call via a live and archived webcast on the company's investor relations website.
Sight Sciences (Nasdaq: SGHT) announced the presentation of new safety and efficacy data from multiple studies of its OMNI Surgical System and TearCare System at the 2021 ASCRS Annual Meeting in Las Vegas from July 23-27. Five papers have been accepted for presentation, focusing on innovative techniques in minimally invasive glaucoma surgery and dry eye treatment. These findings aim to bolster the company's position in addressing prevalent eye diseases.
Sight Sciences, a medical device company, successfully closed its initial public offering (IPO) on July 19, 2021, offering 11.5 million shares at $24.00 each. This includes the full exercise of underwriters' options for an additional 1.5 million shares, resulting in total gross proceeds of approximately $276 million. Trading of Sight Sciences shares commenced on the Nasdaq Global Market under the ticker symbol "SGHT" on July 15, 2021. The offering was managed by Morgan Stanley and BofA Securities, among others.
Sight Sciences has announced the pricing of its initial public offering (IPO) of 10 million shares at $24.00 per share, aiming for total proceeds of $240 million. The IPO is set to close on July 19, 2021, following its trading debut on Nasdaq under the symbol SGHT on July 15, 2021. The underwriters have a 30-day option to purchase up to 1.5 million additional shares. Morgan Stanley and BofA Securities are leading the offering with Citigroup and Piper Sandler also involved. This offering is a crucial step in Sight Sciences' growth strategy in the medical device market.